Description by quasi elastic laser light scattering of a biological preparation: Sarcoplasmic reticulum vesicles

B. Arrio,J. Chevallier,M. Jullien,J. Yon,R. Calvayrac

DOI: https://doi.org/10.1007/BF01870105

Abstract:

What problem does this paper attempt to address?

Glioblastoma vaccine tumor therapy research progress

Tong Zhao,Chunwang Li,Hongliang Ge,Yuanxiang Lin,Dezhi Kang

DOI: https://doi.org/10.1186/s41016-021-00269-7

2022-01-19

Chinese Neurosurgical Journal

Abstract:Abstract Glioblastoma (GBM) is the most common primary malignancy of the central nervous system in adults. The prognosis for late-stage glioblastoma (World Health Organization grade IV astrocytic glioma) is very poor. Novel treatment options are sought after and evaluated by clinicians and researchers, and remarkable advances have been made in surgical techniques, radiotherapy, and chemotherapy. However, the treatment of glioblastoma remains extremely difficult and it can extend the lives of patients by only a few months. There has been notable progress in the field of immunotherapy, particularly with the use of tumor vaccines, for treating glioblastoma; especially peptide vaccines and cell-based vaccines such as dendritic cell vaccines and tumor cell vaccines. However, the results of the current clinical trials for vaccination are not satisfactory. This article reviews the progress in the development of vaccines for glioblastoma.

English Else
Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status

Houssaini,Lamrabet,Nshizirungu,Senhaji,Sekal,Karkouri,Bennis

DOI: https://doi.org/10.3390/vaccines12060655

2024-06-13

Vaccines

Abstract:Glioblastoma (GBM) is the most common and aggressive malignant brain tumor. Standard treatments including surgical resection, radiotherapy, and chemotherapy, have failed to significantly improve the prognosis of glioblastoma patients. Currently, immunotherapeutic approaches based on vaccines, chimeric antigen-receptor T-cells, checkpoint inhibitors, and oncolytic virotherapy are showing promising results in clinical trials. The combination of different immunotherapeutic approaches is proving satisfactory and promising. In view of the challenges of immunotherapy and the resistance of glioblastomas, the treatment of these tumors requires further efforts. In this review, we explore the obstacles that potentially influence the efficacy of the response to immunotherapy and that should be taken into account in clinical trials. This article provides a comprehensive review of vaccine therapy for glioblastoma. In addition, we identify the main biomarkers, including isocitrate dehydrogenase, epidermal growth factor receptor, and telomerase reverse transcriptase, known as potential immunotherapeutic targets in glioblastoma, as well as the current status of clinical trials. This paper also lists proposed solutions to overcome the obstacles facing immunotherapy in glioblastomas.

immunology,medicine, research & experimental
Glioblastoma vaccines: past, present, and opportunities

Zujian Xiong,Itay Raphael,Michael Olin,Hideho Okada,Xuejun Li,Gary Kohanbash

DOI: https://doi.org/10.1016/j.ebiom.2023.104963

IF: 11.205

2024-01-07

EBioMedicine

Abstract:Summary Glioblastoma (GBM) is one of the most lethal central nervous systems (CNS) tumours in adults. As supplements to standard of care (SOC), various immunotherapies improve the therapeutic effect in other cancers. Among them, tumour vaccines can serve as complementary monotherapy or boost the clinical efficacy with other immunotherapies, such as immune checkpoint blockade (ICB) and chimeric antigen receptor T cells (CAR-T) therapy. Previous studies in GBM therapeutic vaccines have suggested that few neoantigens could be targeted in GBM due to low mutation burden, and single-peptide therapeutic vaccination had limited efficacy in tumour control as monotherapy. Combining diverse antigens, including neoantigens, tumour-associated antigens (TAAs), and pathogen-derived antigens, and optimizing vaccine design or vaccination strategy may help with clinical efficacy improvement. In this review, we discussed current GBM therapeutic vaccine platforms, evaluated and potential antigenic targets, current challenges, and perspective opportunities for efficacy improvement.

medicine, research & experimental
Peptide vaccine against glioblastoma: from bench to bedside

Tianrui Yang,Yixin Shi,Tingyu Liang,Hao Xing,Wenbin Ma,Yan Michael Li,Yu Wang

DOI: https://doi.org/10.1007/s44178-022-00021-w

2022-12-17

Holistic Integrative Oncology

Abstract:Glioblastoma accounts for almost half of all intracranial primary malignancies and has the worst prognosis. Because of its high malignancy and frequent recurrence after standard therapy, it is of great significance to explore new therapy options. Recently immune therapy has taken remarkable progress in a variety of tumors, among which peptide vaccines utilize peptide sequences based on tumor-specific antigens or tumor-associated antigen targets to activate self-immune response against tumor cells. However, due to the particularity of intracranial central nervous system tumors, the application of peptide vaccines in glioblastoma still faces challenges. This article mainly reviews the immune basis and important clinical trial results of peptide vaccine therapy for GBM, analyzes the reasons for its poor efficacy, and proposes the development direction of peptide vaccines for the unique challenges of immunotherapy in GBM. An in-depth understanding and elaboration of the application and related issues of peptide vaccine in the treatment of GBM will help to formulate relevant treatment strategies in future clinical and basic research.
Immunotherapy: a promising approach for glioma treatment

Feroza Yasinjan,Yang Xing,Huayue Geng,Rui Guo,Lei Yang,Ziling Liu,Hong Wang

DOI: https://doi.org/10.3389/fimmu.2023.1255611

2023-09-07

Abstract:Gliomas are the most prevalent primary malignant brain tumors worldwide, with glioblastoma (GBM) being the most common and aggressive type. Despite two decades of relentless pursuit in exploring novel therapeutic approaches for GBM, there is limited progress in improving patients' survival outcomes. Numerous obstacles impede the effective treatment of GBM, including the immunosuppressive tumor microenvironment (TME), the blood-brain barrier, and extensive heterogeneity. Despite these challenges, immunotherapies are emerging as a promising avenue that may offer new hope for the treatment of gliomas. There are four main types of immunotherapies for gliomas, immune checkpoint blockades, chimeric antigen receptor T-cell therapies, vaccines, and oncolytic viruses. In addition, gene therapy, bispecific antibody therapy, and combine therapy are also briefly introduced in this review. The significant role of TME in the process of immunotherapies has been emphasized in many studies. Although immunotherapy is a promising treatment for gliomas, enormous effort is required to overcome the existing barriers to its success. Owing to the rapid development and increasing attention paid to immunotherapies for gliomas, this article aims to review the recent advances in immunotherapies for gliomas.
Immunotherapeutic advances in glioma management: The rise of vaccine-based approaches

Wireko Andrew Awuah,Muhammad Hamza Shah,Joecelyn Kirani Tan,Sruthi Ranganathan,Vivek Sanker,Kwadwo Darko,Pearl Ohenewaa Tenkorang,Bryan Badayelba Adageba,Arjun Ahluwalia,Vallabh Shet,Nicholas Aderinto,Mrinmoy Kundu,Toufik Abdul-Rahman,Oday Atallah

DOI: https://doi.org/10.1111/cns.70013

Abstract:Background: Gliomas, particularly glioblastoma multiforme (GBM), are highly aggressive brain tumors that present significant challenges in oncology due to their rapid progression and resistance to conventional therapies. Despite advancements in treatment, the prognosis for patients with GBM remains poor, necessitating the exploration of novel therapeutic approaches. One such emerging strategy is the development of glioma vaccines, which aim to stimulate the immune system to target and destroy tumor cells. Aims: This review aims to provide a comprehensive evaluation of the current landscape of glioma vaccine development, analyzing the types of vaccines under investigation, the outcomes of clinical trials, and the challenges and opportunities associated with their implementation. The goal is to highlight the potential of glioma vaccines in advancing more effective and personalized treatments for glioma patients. Materials and methods: This narrative review systematically assessed the role of glioma vaccines by including full-text articles published between 2000 and 2024 in English. Databases such as PubMed/MEDLINE, EMBASE, the Cochrane Library, and Scopus were searched using key terms like "glioma," "brain tumor," "glioblastoma," "vaccine," and "immunotherapy." The review incorporated both pre-clinical and clinical studies, including descriptive studies, animal-model studies, cohort studies, and observational studies. Exclusion criteria were applied to omit abstracts, case reports, posters, and non-peer-reviewed studies, ensuring the inclusion of high-quality evidence. Results: Clinical trials investigating various glioma vaccines, including peptide-based, DNA/RNA-based, whole-cell, and dendritic-cell vaccines, have shown promising results. These vaccines demonstrated potential in extending survival rates and managing adverse events in glioma patients. However, significant challenges remain, such as therapeutic resistance due to tumor heterogeneity and immune evasion mechanisms. Moreover, the lack of standardized guidelines for evaluating vaccine responses and issues related to ethical considerations, regulatory hurdles, and vaccine acceptance among patients further complicate the implementation of glioma vaccines. Discussion: Addressing the challenges associated with glioma vaccines involves exploring combination therapies, targeted approaches, and personalized medicine. Combining vaccines with traditional therapies like radiotherapy or chemotherapy may enhance efficacy by boosting the immune system's ability to fight tumor cells. Personalized vaccines tailored to individual patient profiles present an opportunity for improved outcomes. Furthermore, global collaboration and equitable distribution are critical for ensuring access to glioma vaccines, especially in low- and middle-income countries with limited healthcare resources CONCLUSION: Glioma vaccines represent a promising avenue in the fight against gliomas, offering hope for improving patient outcomes in a disease that is notoriously difficult to treat. Despite the challenges, continued research and the development of innovative strategies, including combination therapies and personalized approaches, are essential for overcoming current barriers and transforming the treatment landscape for glioma patients.
Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma

Stephen C. Frederico,John C. Hancock,Emily E. S. Brettschneider,Nivedita M. Ratnam,Mark R. Gilbert,Masaki Terabe

DOI: https://doi.org/10.3389/fonc.2021.672508

IF: 4.7

2021-05-10

Frontiers in Oncology

Abstract:The use of immunotherapies for the treatment of brain tumors is a topic that has garnered considerable excitement in recent years. Discoveries such as the presence of a glymphatic system and immune surveillance in the central nervous system (CNS) have shattered the theory of immune privilege and opened up the possibility of treating CNS malignancies with immunotherapies. However, despite many immunotherapy clinical trials aimed at treating glioblastoma (GBM), very few have demonstrated a significant survival benefit. Several factors for this have been identified, one of which is that GBMs are immunologically “cold,” implying that the cancer does not induce a strong T cell response. It is postulated that this is why clinical trials using an immune checkpoint inhibitor alone have not demonstrated efficacy. While it is well established that anti-cancer T cell responses can be facilitated by the presentation of tumor-specific antigens to the immune system, treatment-related death of GBM cells and subsequent release of molecules have not been shown to be sufficient to evoke an anti-tumor immune response effective enough to have a significant impact. To overcome this limitation, vaccines can be used to introduce exogenous antigens at higher concentrations to the immune system to induce strong tumor antigen-specific T cell responses. In this review, we will describe vaccination strategies that are under investigation to treat GBM; categorizing them based on their target antigens, form of antigens, vehicles used, and pairing with specific adjuvants. We will review the concept of vaccine therapy in combination with immune checkpoint inhibitors, as it is hypothesized that this approach may be more effective in overcoming the immunosuppressive milieu of GBM. Clinical trial design and the need for incorporating robust immune monitoring into future studies will also be discussed here. We believe that the integration of evolving technologies of vaccine development, delivery, and immune monitoring will further enhance the role of these therapies and will likely remain an important area of investigation for future treatment strategies for GBM patients.

oncology
Current Immunotherapies for Glioblastoma Multiforme

Boyuan Huang,Xuesong Li,Yuntao Li,Jin Zhang,Zhitao Zong,Hongbo Zhang

DOI: https://doi.org/10.3389/fimmu.2020.603911

IF: 7.3

2021-03-09

Frontiers in Immunology

Abstract:Glioblastoma multiforme (GBM) is the most common and aggressive malignant tumor found in the central nervous system. Currently, standard treatments in the clinic include maximal safe surgical resection, radiation, and chemotherapy and are mostly limited by low therapeutic efficiency correlated with poor prognosis. Immunotherapy, which predominantly focuses on peptide vaccines, dendritic cell vaccines, chimeric antigen receptor T cells, checkpoint inhibitor therapy, and oncolytic virotherapy, have achieved some promising results in both preclinical and clinical trials. The future of immune therapy for GBM requires an integrated effort with rational combinations of vaccine therapy, cell therapy, and radio- and chemotherapy as well as molecule therapy targeting the tumor microenvironment.

immunology
Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma

Jingyu Wang,Fang Shen,Ying Yao,Lin-lin Wang,Yongjian Zhu,Jue Hu

DOI: https://doi.org/10.3389/fonc.2020.00059

IF: 4.7

2020-01-01

Frontiers in Oncology

Abstract:Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults with very poor prognosis and few advances in its treatment. Recently, fast-growing cancer immunotherapy provides a glimmer of hope for GBM treatment. Adoptive cell therapy (ACT) aims at infusing immune cells with direct anti-tumor activity, including tumor-infiltrating lymphocyte (TIL) transfer and genetically engineered T cells transfer. For example, complete regressions in patients with melanoma and refractory lymphoma have been shown by using naturally tumor-reactive T cells and genetically engineered T cells expressing the chimeric anti-CD19 receptor, respectively. Recently, the administration of ACT showed therapeutic potentials for GBM treatment as well. In this review, we summarize the success of ACT in the treatment of cancer and provide approaches to overcome some challenges of ACT to allow its adoption for GBM treatment.
Emerging therapies for glioblastoma: current state and future directions

Liang Rong,Ni Li,Zhenzhen Zhang

DOI: https://doi.org/10.1186/s13046-022-02349-7

2022-04-15

Abstract:Abstract Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an extremely poor prognosis. Given the poor survival with currently approved treatments for GBM, new therapeutic strategies are urgently needed. Advances in decades of investment in basic science of glioblastoma are rapidly translated into innovative clinical trials, utilizing improved genetic and epigenetic profiling of glioblastoma as well as the brain microenvironment and immune system interactions. Following these encouraging findings, immunotherapy including immune checkpoint blockade, chimeric antigen receptor T (CAR T) cell therapy, oncolytic virotherapy, and vaccine therapy have offered new hope for improving GBM outcomes; ongoing studies are using combinatorial therapies with the aim of minimizing adverse side-effects and augmenting antitumor immune responses. In addition, techniques to overcome the blood-brain barrier (BBB) for targeted delivery are being tested in clinical trials in patients with recurrent GBM. Here, we set forth the rationales for these promising therapies in treating GBM, review the potential novel agents, the current status of preclinical and clinical trials, and discuss the challenges and future perspectives in glioblastoma immuno-oncology.

oncology
Prospects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma

Stefanie Tietze,Susanne Michen,Gabriele Schackert,Achim Temme

DOI: https://doi.org/10.1515/iss-2020-0034

2021-03-01

Innovative Surgical Sciences

Abstract:Abstract Glioblastoma multiforme (GBM) is the most prevalent primary brain tumor endowed with a dismal prognosis. Nowadays, immunotherapy in a particular immune checkpoint blockade and therapeutic vaccines are being extensively pursued. Yet, several characteristics of GBM may impact such immunotherapeutic approaches. This includes tumor heterogeneity, the relatively low mutational load of primary GBM, insufficient delivery of antibodies to tumor parenchyma and the unique immunosuppressive microenvironment of GBM. Moreover, standard treatment of GBM, comprising temozolomide chemotherapy, radiotherapy and in most instances the application of glucocorticoids for management of brain edema, results in a further increased immunosuppression. This review will provide a brief introduction to the principles of vaccine-based immunotherapy and give an overview of the current clinical studies, which employed immune checkpoint inhibitors, oncolytic viruses-based vaccination, cell-based and peptide-based vaccines. Recent experiences as well as the latest developments are reviewed. Overcoming obstacles, which limit the induction and long-term immune response against GBM when using vaccination approaches, are necessary for the implementation of effective immunotherapy of GBM.
Advances in Nanotechnology-Based Immunotherapy for Glioblastoma

Lin Tang,Ming Zhang,Chaoyong Liu

DOI: https://doi.org/10.3389/fimmu.2022.882257

IF: 7.3

2022-01-01

Frontiers in Immunology

Abstract:Glioblastoma (GBM) is the most aggressive type of brain tumor. Despite the multimodal therapies, the effectiveness of traditional treatments is not much satisfying. In recent years, immunotherapy has become the focus of tumor treatment. Unlike traditional treatments that directly target tumor cells, immunotherapy uses the body's immune system to kill tumors. However, due to the severe immunosuppressive microenvironment of GBM, it generally has a poor response to immunotherapy. In addition, the existence of the blood-brain barrier (BBB) also compromises the immunotherapeutic efficacy. Therefore, effective immunotherapy of GBM requires the therapeutic agents to not only efficiently cross the BBB but also relieve the strong immunosuppression of the tumor microenvironment of GBM. In this review, we will first introduce the CNS immune system, immunosuppressive mechanism of GBM, and current GBM immunotherapy strategies. Then, we will discuss the development of nanomaterials for GBM immunotherapy based on different strategies, roughly divided into four parts: immune checkpoint therapy, targeting tumor-associated immune cells, activating immune cells through immunogenic cell death, and combination therapy, to provide new insights for future GBM immunotherapy.
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors

Martha R. Neagu,David A. Reardon

DOI: https://doi.org/10.1007/s11864-015-0371-3

2015-10-10

Current Treatment Options in Oncology

Abstract:Opinion statementExisting therapies for glioblastoma (GBM), the most common malignant primary brain tumor in adults, have fallen short of improving the dismal patient outcomes, with an average 14–16-month median overall survival. The biological complexity and adaptability of GBM, redundancy of dysregulated signaling pathways, and poor penetration of therapies through the blood–brain barrier contribute to poor therapeutic progress. The current standard of care for newly diagnosed GBM consists of maximal safe resection, followed by fractionated radiotherapy combined with concurrent temozolomide (TMZ) and 6–12 cycles of adjuvant TMZ. At progression, bevacizumab with or without additional chemotherapy is an option for salvage therapy. The recent FDA approval of sipuleucel-T for prostate cancer and ipilumimab, nivolumab, and pembrolizumab for select solid tumors and the ongoing trials showing clinical efficacy and response durability herald a new era of cancer treatment with the potential to change standard-of-care treatment across multiple cancers. The evaluation of various immunotherapeutics is advancing for GBM, putting into question the dogma of the CNS as an immuno-privileged site. While the field is yet young, both active immunotherapy involving vaccine strategies and cellular therapy as well as reversal of GBM-induced global immune-suppression through immune checkpoint blockade are showing promising results and revealing essential immunological insights regarding kinetics of the immune response, immune evasion, and correlative biomarkers. The future holds exciting promise in establishing new treatment options for GBM that harness the patients’ own immune system by activating it with immune checkpoint inhibitors, providing specificity using vaccine therapy, and allowing for modulation and enhancement by combinatorial approaches.

oncology
[Surgical therapeutic approach with the burn patient].

D. Jacquemin

1989-09-01

Abstract:
Clinical immunotherapy in glioma: current concepts, challenges, and future perspectives

Jun Liu,Jingjian Peng,Jian Jiang,Yanhui Liu

DOI: https://doi.org/10.3389/fimmu.2024.1476436

IF: 7.3

2024-11-02

Frontiers in Immunology

Abstract:Glioma is one of the common tumors in the central nervous system, and its treatment methods (surgery, radiotherapy, and chemotherapy) lack specificity and have a poor prognosis. With the development of immunology, cell biology, and genomics, tumor immunotherapy has ushered in a new era of tumor therapy, achieving significant results in other invasive cancers such as advanced melanoma and advanced non-small cell lung cancer. Currently, the clinical trials of immunotherapy in glioma are also progressing rapidly. Here, this review summarizes promising immunotherapy methods in recent years, reviews the current status of clinical trials, and discusses the challenges and prospects of glioma immunotherapy.

immunology
Research Progress in Immunotherapy of Gliomas

Zhi-hong Duan,Zi-long Wei

DOI: https://doi.org/10.31083/j.jin2205118

2023-01-01

Journal of Integrative Neuroscience

Abstract:Although some progress has been made in tumor treatment, gliomas remain one of the tumors that can still seriously threaten human life and health. Due to the particularity of the immune microenvironment of the central nervous system and the strong invasiveness of tumors, the treatment of gliomas remains a major challenge. Currently, researchers have explored a large number of immunotherapy programs to improve the survival and prognosis of glioma patients, including tumor vaccines, immune checkpoint inhibitors, adoptive cell transfer therapy, viral vector therapy, and genetic engineering therapy. The goal of these programs is to activate or change the immunosuppressive environment and target tumor cells through drugs, combined with surgical resection, radiotherapy, chemotherapy, and anti-angiogenesis drugs, to achieve the purpose of treating glioma. This review briefly describes the immunosuppressive microenvironment of gliomas and summarizes recent immunotherapeutic strategies and their progress. The aim is to summarize the latest immunotherapies for the treatment of gliomas and provide new research directions.
Immunotherapeutic Advancements for Glioblastoma

Leonel Ampie,Eric C. Woolf,Christopher Dardis

DOI: https://doi.org/10.3389/fonc.2015.00012

IF: 4.7

2015-01-29

Frontiers in Oncology

Abstract:Immunotherapy seeks to improve the body's immune response to a tumor. Currently, the principal mechanisms employed are: (1) to improve an aspect of the immune response (e.g., T cell activation) and (2) to encourage the targeting of particular antigens. The latter is typically achieved by exposing the immune system to the antigen in question, in vivo, or in vitro followed by re-introduction of the primed cells to the body. The clinical relevance of these approaches has already been demonstrated for solid tumors such as melanoma and prostate cancer. The central nervous system was previously thought to be immune privileged. However, we know now that the immune system is highly active in the brain and interacts with brain tumors. Thus, harnessing and exploiting this interaction represents an important approach for treating malignant brain tumors. We present a summary of progress in this area, focusing particularly on immune-checkpoint inhibition, vaccines, and T cell engineering.

oncology
Clinical and Translational Advances in Glioma Immunotherapy

Lukas Bunse,Theresa Bunse,Christopher Krämer,Yu-Chan Chih,Michael Platten

DOI: https://doi.org/10.1007/s13311-022-01313-9

IF: 6.088

2022-10-29

Neurotherapeutics

Abstract:Gliomas are highly treatment refractory against immune checkpoint blockade, an immunotherapeutic modality that revolutionized therapy for many tumors. At the same time, technological innovation has dramatically accelerated the development of immunotherapeutic approaches such as personalized tumor-specific vaccine production, dendritic cell vaccine manufacture, patient-individual target selection and chimeric antigen receptor, and T cell receptor T cell manufacture. Here we review recent clinical and translational advances in glioma immunotherapy with a focus on targets and their cognate immune receptor derivates as well as concepts to improve intratumoral T cell effector functions.

pharmacology & pharmacy,neurosciences,clinical neurology
Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions

Mingming Wang,Xiaojie Wang,Xiaoyan Jin,Jingjing Zhou,Yufu Zhang,Yiyuan Yang,Yusi Liu,Jing Zhang

DOI: https://doi.org/10.3389/fimmu.2023.1175118

IF: 7.3

2023-05-25

Frontiers in Immunology

Abstract:Glioblastoma (GBM) is among the most fatal and recurring malignant solid tumors. It arises from the GBM stem cell population. Conventional neurosurgical resection, temozolomide (TMZ)-dependent chemotherapy and radiotherapy have rendered the prognosis of patients unsatisfactory. Radiotherapy and chemotherapy can frequently induce non-specific damage to healthy brain and other tissues, which can be extremely hazardous. There is therefore a pressing need for a more effective treatment strategy for GBM to complement or replace existing treatment options. Cell-based and cell-free immunotherapies are currently being investigated to develop new treatment modalities against cancer. These treatments have the potential to be both selective and successful in minimizing off-target collateral harm in the normal brain. In this review, several aspects of cell-based and cell-free immunotherapies related to GBM will be discussed.

immunology
Existence of extraordinary zero-curvature slowness curve in anisotropic elastic media.

Litian Wang,Kent G Ryne

DOI: https://doi.org/10.1121/1.2770546

2007-09-26

Abstract:Acoustic wave propagation in elastic media is characterized by the slowness surface. The slowness surface consists of three sheets associated with three modes of wave propagation and the two outer sheets can have zero-curvature locally. It is shown that the outmost sheet can admit extraordinary zero-curvature and the slowness curve can appear as a straight line locally. Using the perturbation method, the conditions for the extraordinary zero-curvature are derived analytically without violating the thermodynamic condition for elastic media. The results can be applied to crystals with higher symmetry and to the study of phonon focusing and surface waves.

Description by quasi elastic laser light scattering of a biological preparation: Sarcoplasmic reticulum vesicles

Glioblastoma vaccine tumor therapy research progress

Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status

Glioblastoma vaccines: past, present, and opportunities

Peptide vaccine against glioblastoma: from bench to bedside

Immunotherapy: a promising approach for glioma treatment

Immunotherapeutic advances in glioma management: The rise of vaccine-based approaches

Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma

Current Immunotherapies for Glioblastoma Multiforme

Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma

Emerging therapies for glioblastoma: current state and future directions

Prospects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma

Advances in Nanotechnology-Based Immunotherapy for Glioblastoma

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors

[Surgical therapeutic approach with the burn patient].

Clinical immunotherapy in glioma: current concepts, challenges, and future perspectives

Research Progress in Immunotherapy of Gliomas

Immunotherapeutic Advancements for Glioblastoma

Clinical and Translational Advances in Glioma Immunotherapy

Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions

Existence of extraordinary zero-curvature slowness curve in anisotropic elastic media.